{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T18:35:26Z","timestamp":1764700526429},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"crossref","award":["84456"],"award-info":[{"award-number":["84456"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.pupt.2015.03.004","type":"journal-article","created":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T12:51:35Z","timestamp":1428238295000},"page":"7-14","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Therapeutic efficacy of liposomes containing 4-(5-pentadecyl-1,3,4-oxadiazol-2-yl)pyridine in a murine model of progressive pulmonary tuberculosis"],"prefix":"10.1016","volume":"32","author":[{"given":"Dulce","family":"Mata-Espinosa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria Mar\u00eda","family":"Molina-Salinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Barrios-Pay\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Navarrete-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Marquina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Octavio","family":"Ramos-Espinosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estela Isabel","family":"Bini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Baeza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogelio","family":"Hern\u00e1ndez-Pando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2015.03.004_bib1","series-title":"Global Tuberculosis Report 2014","author":"WHO","year":"2014"},{"key":"10.1016\/j.pupt.2015.03.004_bib2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1590\/0074-0276108022013006","article-title":"A population-based study of first and second-line drug-resistant tuberculosis in a high-burden area of the Mexico\/United States border","volume":"108","author":"Becerril-Montes","year":"2012","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.pupt.2015.03.004_bib3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1086\/590009","article-title":"Extensively drug-resistant tuberculosis in California, 1993\u20132006","volume":"47","author":"Banerjee","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pupt.2015.03.004_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/cid\/cit167","article-title":"A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients","volume":"57","author":"Pasipanodya","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pupt.2015.03.004_bib5","first-page":"1087","article-title":"Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection","volume":"36","author":"Sagwa","year":"2013","journal-title":"Expert. Opin. Drug Saf."},{"key":"10.1016\/j.pupt.2015.03.004_bib6","doi-asserted-by":"crossref","first-page":"e58817","DOI":"10.1371\/journal.pone.0058817","article-title":"Serious treatment related adverse drug reactions amongst anti-retroviral na\u00efve MDR-TB patients. (Abstract)","volume":"8","author":"Van der Walt","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pupt.2015.03.004_bib7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.5588\/ijtld.12.0277","article-title":"New drugs for the treatment of tuberculosis: hope and reality","volume":"16","author":"Grosset","year":"2012","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"10.1016\/j.pupt.2015.03.004_bib8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2174\/156802612799984526","article-title":"Natural products as leads for tuberculosis drug development","volume":"12","author":"Salomon","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.pupt.2015.03.004_bib9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10482-012-9777-0","article-title":"Exploring anti-TB leads from natural products library originated from marine microbes and medicinal plants","volume":"102","author":"Liu","year":"2012","journal-title":"A Van Leeuw. J. Microbiol."},{"key":"10.1016\/j.pupt.2015.03.004_bib10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nrd4001","article-title":"Advances in the development of new tuberculosis drugs and treatment regimens","volume":"12","author":"Zumla","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pupt.2015.03.004_bib11","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1517\/13543784.2012.724397","article-title":"Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment","volume":"21","author":"Engohang-Ndong","year":"2012","journal-title":"Expert. Opin. Invest. Drugs"},{"key":"10.1016\/j.pupt.2015.03.004_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2012.02.033","article-title":"Tuberculosis: the drug development pipeline at a glance","volume":"51","author":"Villemagne","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.pupt.2015.03.004_bib13","unstructured":"STOP TB Partnership, Working Group on New TB Drugs, Available at: http:\/\/www.newtbdrugs.org\/pipeline.php (last accessed 05.12.14.)."},{"key":"10.1016\/j.pupt.2015.03.004_bib14","series-title":"The use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis. Interim Policy Guidance","author":"WHO","year":"2013"},{"key":"10.1016\/j.pupt.2015.03.004_bib15","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1574-6976.2011.00302.x","article-title":"Pathogenesis in tuberculosis: transcriptomic approaches to unraveling virulence mechanisms and finding new drug targets","volume":"36","author":"Mukhopadhyay","year":"2012","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.pupt.2015.03.004_bib16","first-page":"217","article-title":"Exploring prospects of novel drugs for tuberculosis","volume":"6","author":"Janssen","year":"2012","journal-title":"Drug Des Dev Ther."},{"key":"10.1016\/j.pupt.2015.03.004_bib17","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4155\/fmc.10.214","article-title":"New strategies in fighting TB: targeting Mycobacterium tuberculosis-secreted phosphatases MptpA & MptpB","volume":"2","author":"Silva","year":"2010","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.pupt.2015.03.004_bib18","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4155\/fmc.10.220","article-title":"Discovery of anti-TB agents that target the cell-division protein FtsZ","volume":"2","author":"Kumar","year":"2010","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.pupt.2015.03.004_bib19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2174\/157489111796064579","article-title":"Inhibition of drug efflux in mycobacteria with phenothiazines and other putative efflux inhibitors","volume":"6","author":"Rodrigues","year":"2011","journal-title":"Recent Pat. Antiinfect Drug Discov."},{"key":"10.1016\/j.pupt.2015.03.004_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ejmech.2014.05.005","article-title":"Synthesis of novel 1,2,3-triazole derivatives of isoniazid and their in vitro and in vivo antimycobacterial activity evaluation","volume":"81","author":"Kumar","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.pupt.2015.03.004_bib21","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1016\/j.bmc.2005.03.013","article-title":"Antimycobacterial activity of new 3-substituted 5-(pyridine-4-yl)-3H-1,3,4-oxadiazol-2-one and 2-thione derivatives. Preliminary molecular modeling investigations","volume":"13","author":"Mamolo","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.pupt.2015.03.004_bib22","doi-asserted-by":"crossref","first-page":"10192","DOI":"10.3390\/molecules170910192","article-title":"Synthetic approaches and pharmacological activity of 1,3,4-oxadiazoles: a review of the literature from 2000-2012","volume":"17","author":"de Oliveira","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.pupt.2015.03.004_bib23","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2174\/138955712801264800","article-title":"1,3,4-oxadiazole: a biologically active scaffold","volume":"12","author":"Khalilullah","year":"2012","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.pupt.2015.03.004_bib24","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.carres.2011.03.004","article-title":"Synthesis of variously coupled conjugates of D-glucose, 1,3,4-oxadiazole, and 1,2,3-triazole for inhibition of glycogen phosphorylase","volume":"346","author":"Kun","year":"2011","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.pupt.2015.03.004_bib25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cbi.2009.07.014","article-title":"Vasorelaxant effect in rat aortic rings through calcium channel blockage: a preliminary in vitro assessment of a 1,3,4-oxadiazole derivative","volume":"181","author":"Bankar","year":"2009","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.pupt.2015.03.004_bib26","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3109\/14756366.2010.550890","article-title":"Synthesis and biological evaluation of 2,5-disubstituted 1,3,4-oxadiazole derivatives with both COX and LOX inhibitory activity","volume":"26","author":"Akhter","year":"2011","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.pupt.2015.03.004_bib27","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1016\/j.ejmech.2009.04.006","article-title":"Synthesis and pharmacological evaluation of 1,3,4-oxadiazole bearing bis (heterocycle) derivatives as anti-inflammatory and analgesic agents","volume":"44","author":"Jayashankar","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.pupt.2015.03.004_bib28","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.bmcl.2005.04.018","article-title":"Design and synthesis of new 2-substituted-5-(2-benzylthiophenyl)-1,3,4- oxadiazoles as benzodiazepine receptor agonists","volume":"15","author":"Zarghi","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.pupt.2015.03.004_bib29","first-page":"58","article-title":"Synthesis and antiproliferative assay of 1,3,4-oxadiazole and 1,2,4-triazole derivatives in cancer cells","volume":"7","author":"Tu","year":"2013","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.pupt.2015.03.004_bib30","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1016\/j.ejmech.2010.08.003","article-title":"Design, synthesis and biological evaluation of 1,3,4-oxadiazole derivatives","volume":"45","author":"Jha","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.pupt.2015.03.004_bib31","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.ejmech.2011.01.015","article-title":"Synthesis of some novel 3-(1-(1-substitutedpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)-5-substituted phenyl-1,2,4-oxadiazoles as antifungal agents","volume":"46","author":"Sangshetti","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.pupt.2015.03.004_bib32","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2174\/138955711797655407","article-title":"1,3,4-oxadiazole: a privileged structure in antiviral agents","volume":"11","author":"Li","year":"2011","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.pupt.2015.03.004_bib33","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1016\/j.bmc.2007.05.053","article-title":"Synthesis and antimycobacterial activity of 4-(5-substituted-1,3,4-oxadiazol-2-yl)pyridines","volume":"15","author":"Navarrete-V\u00e1zquez","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.pupt.2015.03.004_bib34","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1021\/jm701560p","article-title":"1,5-Diphenylpyrrole derivatives as antimycobacterial agents. Probing the influence on antimycobacterial activity of lipophilic substituents at the phenyl rings","volume":"51","author":"Biava","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pupt.2015.03.004_bib35","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1016\/j.ejmech.2009.06.005","article-title":"1,5-Diaryl-2-ethyl pyrrole derivatives as antimycobacterial agents: design, synthesis, and microbiological evaluation","volume":"44","author":"Biava","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.pupt.2015.03.004_bib36","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.bmc.2008.12.070","article-title":"Synthesis and biological evaluation of some new 1,4-dihydropyridines containing different ester substitute and diethyl carbamoyl group as anti-tubercular agents","volume":"17","author":"Khoshneviszadeh","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.pupt.2015.03.004_bib37","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1016\/j.ejmech.2009.07.015","article-title":"Pentacyclo-undecane derived cyclic tetra-amines: synthesis and evaluation as potent anti-tuberculosis agents","volume":"44","author":"Onajole","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.pupt.2015.03.004_bib38","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/09687688.2012.667577","article-title":"Molecular organization of the non-bilayer phospholipid arrangements that induce an autoimmune disease resembling human lupus in mice","volume":"29","author":"Wong-Baeza","year":"2012","journal-title":"Mol. Membr. Biol."},{"key":"10.1016\/j.pupt.2015.03.004_bib39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.arcmed.2005.04.010","article-title":"Bactericidal activity of organic extracts from Flourensia cernua DC against strains of Mycobacterium tuberculosis","volume":"37","author":"Molina-Salinas","year":"2006","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.pupt.2015.03.004_bib40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/10520298009067249","article-title":"The use of fluorescein diacetate and ethidium bromide as a stain for evaluating viability of mycobacteria","volume":"55","author":"Jarnagin","year":"1980","journal-title":"Stain Technol."},{"key":"10.1016\/j.pupt.2015.03.004_bib41","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/bmj.1.4854.130","article-title":"Bactericidal activity of streptomycin and isoniazid against tubercle bacilli","volume":"1","author":"Singh","year":"1954","journal-title":"BMJ Br. Med. J."},{"key":"10.1016\/j.pupt.2015.03.004_bib42","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1365-2958.2006.05467.x","article-title":"Mechanisms of action of isoniazid","volume":"62","author":"Timmins","year":"2006","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.pupt.2015.03.004_bib43","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.bmc.2007.01.030","article-title":"Antituberculosis drugs: ten years of research","volume":"15","author":"Janin","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.pupt.2015.03.004_bib44","first-page":"1034","article-title":"Some recently synthesised tuberculostatic 4-substituted oxadiazolones and oxadiazol-thiones. VI","volume":"16","author":"Wilder-Smith","year":"1966","journal-title":"Arzneim. Forsch."},{"key":"10.1016\/j.pupt.2015.03.004_bib45","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1128\/CMR.00060-05","article-title":"Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy","volume":"19","author":"Warner","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.pupt.2015.03.004_bib46","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2249.2006.03049.x","article-title":"A combination of transforming growth factor-\u03b2 antagonists and an inhibitor of cyclooxygenase inhibitors is an effective treatment for murine pulmonary tuberculosis","volume":"144","author":"Hern\u00e1ndez Pando","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.pupt.2015.03.004_bib47","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1086\/426453","article-title":"16-\u03b1-Bromoepiandrosterone restores T helper cell type 1 activity and accelerates chemotherapy-induced bacterial clearance in a model of progressive pulmonary tuberculosis","volume":"191","author":"Hern\u00e1ndez Pando","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.pupt.2015.03.004_bib48","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jconrel.2007.10.027","article-title":"Delivery systems to increase the selectivity of antibiotics in phagocytic cells","volume":"125","author":"Briones","year":"2008","journal-title":"J. Control Release"},{"key":"10.1016\/j.pupt.2015.03.004_bib49","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.drudis.2012.03.012","article-title":"Tuberculosis: from molecular pathogenesis to effective drug carrier design","volume":"17","author":"Dube","year":"2012","journal-title":"Drug Discov. Today"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553915000395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553915000395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T19:00:02Z","timestamp":1537729202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553915000395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":49,"alternative-id":["S1094553915000395"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2015.03.004","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic efficacy of liposomes containing 4-(5-pentadecyl-1,3,4-oxadiazol-2-yl)pyridine in a murine model of progressive pulmonary tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2015.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}